ClinicalTrials.gg
Status unknownNCT03999437Updated Jun 26, 2019

SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS

A Phase 2 interventional study of TERBINAFINE HYDROCHLORIDE (1%) and BUTENAFINE HYDROCHLORIDE (1%) in Tinea Pedis, sponsored by United Laboratories. Status unknown at 1 site in Philippines. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by United Laboratories · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2019, registered Jun 2019).
Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis of tinea pedia involves clinical symptoms as well as microscopic examination. Topical therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control in adult Filipino patients with athlete's foot. This study will benefit the Filipino community by helping us determine which anti-fungal cream is most effective for athlete's foot.

02

Conditions studied

  • Tinea Pedis

Browse trials for

03

In context

Tinea Pedis

73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.

This study's planned enrollment of 42 is below the median of 128 across 66 interventional studies indexed under Tinea Pedis.

Browse Tinea Pedis studies →

Lead sponsor

United Laboratories is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or nonpregnant females aged 18-60 years old.
  • Clinical diagnosis of tinea pedis (total sign/symptom score >2), lesions between the toes, with possible extension to the lateral surfaces and soles of the feet confirmed by a positive microscopy prior to dosing.
  • Willing to sign the .

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant (confirmed by a pregnancy test), suspect themselves to be pregnant (even if pregnancy test is negative), breast-feeding, or planning a pregnancy.
  • Signs of systemic or other superficial fungal disease (e.g.onychomycosis), abnormal findings upon physical examination of the foot or previous treatment with a disallowed medication (such as ).
  • Presence of non-healing wounds and/or bacterial infection on the feet.
  • Secondary bacterial infection due to tinea pedis
  • Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment areas, which could interfere with the rating of efficacy parameters.
  • History of to any component of the test products.
  • Current imuunosuppression. Specifically, these include patients with co-morbidities such as diabetes, , chronic diseases requiring maintenance medications, acute febrile/infectious illnesses (i.e. Dengue, pneumonia, etc)
  • Use within 3 months prior to baseline of: 1.) chemotherapy, or 2.) radiation therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Treatment # 1

    Drug: TERBINAFINE HYDROCHLORIDE (1%)

  • Experimental
    Treatment # 2

    Drug: BUTENAFINE HYDROCHLORIDE (1%)

  • Placebo comparator
    Placebo Control

    Drug: Vehicle Control

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with effective treatment at week 6

    Defined as negative microscopy and improvement in signs and symptoms: mild or no erythema, desquamation or pruritis (\<=1), no vesiculation, and a total sign/symptom score of \<=2.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Clinical Trial Management and Testing Associates, Inc.
    Muntinlupa, Philippines
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Dec 2019, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2019
First posted
Jun 26, 2019
StartActual
Jan 2, 2019
Primary completionEst.
Dec 13, 2019
CompletionEst.
Jan 3, 2020
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03999437
Lead sponsor
United Laboratories
Responsible party
Sponsor
First posted
Jun 26, 2019
Start date
Jan 2, 2019
Primary completion
Dec 13, 2019 (estimated)
Completion
Jan 3, 2020 (estimated)
Last update
Jun 26, 2019

Study contacts

Juliene Co, PhD
Contact
julieneco@gmail.com
(632)8580001 ext. 8553

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Terbinafine · Butenafine

Start the discussion